Drug Approval | August 28, 2024
Zydus receives USFDA final approval for Amantadine ER capsules 68.5 mg
Also received tentative approval for 137 mg
Also received tentative approval for 137 mg
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
e brings over 27+ years of rich pharmaceutical experience
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
Subscribe To Our Newsletter & Stay Updated
